Operating
Accretion (Amortization) of Investment Discounts and Premiums
Neurocrine Biosciences Accretion (Amortization) of Investment Discounts and Premiums decreased by 35.0% to $1.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 71.7%, from $4.60M to $1.30M. Over 4 years (FY 2021 to FY 2025), Accretion (Amortization) of Investment Discounts and Premiums shows an upward trend with a 14.5% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
Metric ID:
schw_accretion_amortization_investment_discountsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.85M | -$1.85M | -$1.85M | -$925.00K | -$925.00K | -$925.00K | -$925.00K | $2.10M | $3.90M | $6.00M | $6.30M | $7.10M | $7.00M | $6.50M | $5.60M | $4.60M | $3.40M | $2.70M | $2.00M | $1.30M |
| QoQ Change | — | +0.0% | +0.0% | +50.0% | +0.0% | +0.0% | +0.0% | +327.0% | +85.7% | +53.8% | +5.0% | +12.7% | -1.4% | -7.1% | -13.8% | -17.9% | -26.1% | -20.6% | -25.9% | -35.0% |
| YoY Change | — | — | — | — | +50.0% | +50.0% | +50.0% | +327.0% | +521.6% | +748.6% | +781.1% | +238.1% | +79.5% | +8.3% | -11.1% | -35.2% | -51.4% | -58.5% | -64.3% | -71.7% |
Range-$1.85M – $7.10M
CAGR-7.2%
Avg YoY Growth+160.1%
Median YoY Growth+50.0%
Current Streak8 quarters decline
Accretion (Amortization) of Investment Discounts and Premiums at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's accretion (amortization) of investment discounts and premiums?
- Neurocrine Biosciences (NBIX) reported accretion (amortization) of investment discounts and premiums of $1.30M in Q1 2026.
- How has Neurocrine Biosciences's accretion (amortization) of investment discounts and premiums changed year-over-year?
- Neurocrine Biosciences's accretion (amortization) of investment discounts and premiums decreased by 71.7% year-over-year, from $4.60M to $1.30M.
- What is the long-term trend for Neurocrine Biosciences's accretion (amortization) of investment discounts and premiums?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's accretion (amortization) of investment discounts and premiums has grown at a 14.5% compound annual growth rate (CAGR), from -$7.40M to $12.70M.